NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
23 Mar 2017

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

BioClin Therapeutics, Inc., announced today the closing of a $30 million Series B financing.

22 Mar 2017

Minoryx Therapeutics successfully completes phase 1 clinical trial for lead candidate MIN-102

Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that it has successfully completed its phase 1 trial with MIN-102.
20 Mar 2017

MedLumics Secures 34.4 Million Euros in Series B Funding

MedLumics announced today that it has raised 34.4 million Euros in financing that will be used to help advance the product and clinical development of the company’s AblaView catheter
13 Mar 2017

TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction

TiGenix NV today announced top-line one-year results from the CAREMI clinical trial, an exploratory Phase I/II study of AlloCSCs in acute myocardial infarction (AMI).
09 Mar 2017

TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial

TiGenix NV today announced week 104 data from the Cx601 ADMIRE-CD study, a pivotal Phase III trial for complex perianal fistulas in Crohn’s disease patients. 
07 Mar 2017

TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol

TiGenix NV announced today that it has received positive feedback from the U.S. Food and Drug Administration (FDA) on an improved protocol for its global Phase III trial for the treatment of complex perianal fistulas in Crohn’s disease patients. 
06 Mar 2017

TiGenix Provides Update on Cx601 Marketing Authorization Application procedure in Europe

TiGenix NV announces that it has received the Day 180 List of Outstanding Issues (LoOI) from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) and expects to receive a Marketing Authorization decision for Cx601 in 2017. 
22 Feb 2017

Minoryx Therapeutics receives Orphan Drug Designation from the US FDA for its lead candidate MIN-102

Minoryx Therapeutics, today announces that its lead compound MIN-102 has been granted Orphan Drug Designation by the US Food and Drug Administration body (FDA).
17 Feb 2017

Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn’s Disease Patients with Cx601

Takeda Pharmaceutical Company today announced new data from the Phase 3 ADMIRE-CD clinical trial.
08 Feb 2017

Dr Claude Nicaise joins Minoryx Therapeutics as independent board member

Minoryx Therapeutics, a drug development company specialized in the discovery of new drugs for orphan diseases, today announces that Dr Claude Nicaise has joined its board of directors as an independent member.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.